APA (7th ed.) Citation

Armstrong, A., Bui, C., Fitch, K., Sawhney, T. G., Brown, B., Flanders, S., . . . Chambers, J. (2017). Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: Cost of care in Medicare and commercial populations. Current Medical Research & Opinion, 33(6), 1133. https://doi.org/10.1080/03007995.2017.1308919

Chicago Style (17th ed.) Citation

Armstrong, A., C. Bui, K. Fitch, T. Goss Sawhney, B. Brown, S. Flanders, M. Balk, J. Deangelis, and J. Chambers. "Docetaxel Chemotherapy in Metastatic Castration-resistant Prostate Cancer: Cost of Care in Medicare and Commercial Populations." Current Medical Research & Opinion 33, no. 6 (2017): 1133. https://doi.org/10.1080/03007995.2017.1308919.

MLA (9th ed.) Citation

Armstrong, A., et al. "Docetaxel Chemotherapy in Metastatic Castration-resistant Prostate Cancer: Cost of Care in Medicare and Commercial Populations." Current Medical Research & Opinion, vol. 33, no. 6, 2017, p. 1133, https://doi.org/10.1080/03007995.2017.1308919.